Intco Medical Technology Co Ltd
SZSE:300677
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (16.6), the stock would be worth ¥29 (50% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 33 | ¥57.79 |
0%
|
| 3-Year Average | 16.6 | ¥29 |
-50%
|
| 5-Year Average | 4 | ¥7.05 |
-88%
|
| Industry Average | 29.4 | ¥51.48 |
-11%
|
| Country Average | 28.9 | ¥50.59 |
-12%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
¥22.1B
|
/ |
Oct 2025
¥991.9m
|
= |
|
|
¥22.1B
|
/ |
Dec 2025
¥927m
|
= |
|
|
¥22.1B
|
/ |
Dec 2026
¥1.3B
|
= |
|
|
¥22.1B
|
/ |
Dec 2027
¥1.7B
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.8B CNY | 33 | 22.2 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY | 34 | 39.1 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.9B CHF | 27.8 | 37.1 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
93.1B DKK | 14.6 | 23 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.5B USD | 19.7 | 33 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.3B GBP | 17.8 | 32.4 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 54.5 | -15.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
879B JPY | 31.9 | 49.7 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.3B CNY | 20.3 | 22.6 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | -76.7 | -36.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.6 |
| Median | 28.9 |
| 70th Percentile | 52.9 |
| Max | 49 021 |
Other Multiples
Intco Medical Technology Co Ltd
Glance View
In the bustling industrial landscape of China, Intco Medical Technology Co., Ltd. has carved a distinctive niche as a significant player in the production and global distribution of disposable medical products. Established in 2009, the company has orchestrated its growth strategy by focusing on the manufacture of essential medical consumables like gloves, face masks, thermal plastics, and non-woven products. Intco's operations are adeptly integrated, with facilities strategically located to optimize manufacturing efficiencies and logistical ease, facilitating swift distribution to over 100 countries. This strategic footprint ensures that products are rapidly dispatched to meet the ever-increasing demands of global healthcare markets. Driving the company’s financial engine is its diversified product portfolio, tailored to cater to a wide array of healthcare needs, from hospitals to individual consumers who prioritize personal health safety. The company monetizes its offerings through a robust sales network, leveraging both direct sales channels and partnerships with global distributors. While the COVID-19 pandemic played a role in increasing demand for personal protective equipment, Intco has sustained its profitability through a commitment to quality and innovation, continuously expanding its research and development initiatives. By maintaining a balance between high-volume production and stringent quality control, Intco Medical Technology thrives as a cornerstone in the healthcare supply chain, adeptly navigating the dynamics of a rapidly evolving industry.
